SCHEMBL3020191

SCHEMBL3020191

Cc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4c(F)c(F)c(F)c(F)c4F)CC3)n2)cc1C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPK1 P28482 2/20 0.39
LMNA P02545 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 3/20 0.38
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PKM P14618 3/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
HTT P42858 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007546 0.90 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA
SCHEMBL3016674 0.89 NPSR1 (0.43) ALDH1A1MAPK1LMNAMEN1KMT2A
SCHEMBL3018025 0.89 KMT2A (0.45) ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA
SCHEMBL3002005 0.89 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA
SCHEMBL3002027 0.88 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA
SCHEMBL3001244 0.87 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA
SCHEMBL3017538 0.87 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA
SCHEMBL3017922 0.87 MAPT (0.41) ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA
SCHEMBL3653984 0.87 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA
SCHEMBL3017854 0.87 L3MBTL1 (0.41) ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.